Concurrent or layered treatment with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Shore, Neal D.
Sartor, A. Oliver
Sternberg, Cora N.
Saad, Fred
Tombal, Bertrand F.
Miller, Kurt
Kalinovsky, Jan
Jiao, XiaoLong
Tangirala, Krishna
Higano, Celestia S.
机构：
[1] Carolina Urol Res Ctr, Myrtle Beach, SC USA
[2] Tulane Med Sch, New Orleans, LA USA
[3] Weill Cornell Med, Englander Inst Precis Med, New York, NY USA
[4] Ctr Hosp Univ Montreal CRCHUM, Montreal, PQ, Canada
[5] Catholic Univ Louvain, Brussels, Belgium
[6] Charite, Dept Urol, Berlin, Germany
[7] Bayer Healthcare Pharmaceut Inc, Basel, Switzerland
[8] Bayer HealthCare Pharmaceut, Whippany, NJ USA
[9] Bayer Healthcare Pharmaceut Inc, Whippany, NJ 07981 USA
[10] Univ Washington, Seattle, WA 98195 USA
[11] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.5026
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5026
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Concurrent or layered treatment (Tx) with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Shore, Neal D.
    Sartor, Oliver A.
    Sternberg, Cora N.
    Saad, Fred
    Tombal, Bertrand F.
    Miller, Kurt
    Kalinovsky, Jan
    Jiao, Xiaolong
    Tangirala, Krishna
    Higano, Celestia S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [2] Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer
    Shore, Neal
    Higano, Celestia S.
    George, Daniel J.
    Sternberg, Cora N.
    Saad, Fred
    Tombal, Bertrand
    Miller, Kurt
    Kalinovsky, Jan
    Jiao, XiaoLong
    Tangirala, Krishna
    Sartor, Oliver
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2020, 23 (04) : 680 - 688
  • [3] Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer
    Neal Shore
    Celestia S. Higano
    Daniel J. George
    Cora N. Sternberg
    Fred Saad
    Bertrand Tombal
    Kurt Miller
    Jan Kalinovsky
    XiaoLong Jiao
    Krishna Tangirala
    Oliver Sartor
    [J]. Prostate Cancer and Prostatic Diseases, 2020, 23 : 680 - 688
  • [4] Clinical Outcomes With Concurrent or Layered Treatment With Radium-223 and Abiraterone Plus Prednisone/Prednisolone: A Retrospective Study of Real-World Experience With Patients With Metastatic Castration-Resistant Prostate Cancer
    不详
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (04) : 5 - 6
  • [5] Clinical outcome with radium-223 (Ra-223) in patients (pts) previously treated with abiraterone (Abi) or enzalutamide (Enza): A retrospective study of real-world (RW) data from pts with metastatic castrationresistant prostate cancer (mCRPC)
    Higano, C. S.
    Tombal, B.
    Miller, K.
    Saad, F.
    Sartor, O.
    Tangirala, K.
    Jiao, X.
    Kalinovsky, J.
    Sternberg, C. N.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [6] Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    George, Daniel J.
    Sternberg, Cora N.
    Sartor, A. Oliver
    Saad, Fred
    Tombal, Bertrand F.
    Miller, Kurt
    Kalinovsky, Jan
    Jiao, XiaoLong
    Tangirala, Krishna
    Higano, Celestia S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [7] Combination treatment with radium-223 (223Ra) and enzalutamide (enza) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the REASSURE study
    Tombal, B.
    Goebell, P. J.
    Shore, N. D.
    George, D. J.
    Pinto, A.
    Sartor, O.
    Meltzer, J.
    Verholen, F.
    Schmall, A.
    Saad, F.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S984 - S984
  • [8] UTILIZATION OF RADIUM-223 DICHLORIDE (RA-223) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CANADA: A REAL-WORLD RETROSPECTIVE STUDY
    Lapierre, M.
    Fraelic, A.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A162 - A162
  • [9] A phase IIa study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
    Petrylak, D. P.
    Vaishampayan, U. N.
    Patel, K. R.
    Higano, C. S.
    Albany, C.
    Dawson, N. A.
    Mehlhaff, B. A.
    Quinn, D. I.
    Nordquist, L. T.
    Wagner, V. J.
    Shen, J.
    Trandafir, L.
    Sartor, O.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 340 - 341
  • [10] Pain efficacy with radium-223 (Ra-223) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the PARABO observational study
    Palmedo, H.
    Ahmadzadehfar, H.
    Eschmann, S.
    Selkinski, I.
    Straube, F.
    Niesen, A.
    Schoenberger, J.
    Barsegian, V.
    Liepe, K.
    Mottaghy, F. M.
    Guan, R.
    Pinkert, J.
    Buetikofer, S.
    Herrmann, K.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S641 - S641
12345